| 1 |
34656068 | CYP2C19 Loss-of-function Polymorphisms are Associated with Reduced Risk of Sulfonylurea Treatment Failure in Chinese Patients with Type 2 Diabetes. | 2022 Feb |
5 |
| 2 |
33731883 | Pharmacogenetic-guided glimepiride therapy in type-2 diabetes mellitus: a cost-effectiveness study. | 2021 Oct |
2 |
| 3 |
33840516 | Association Between the CYP2C9 Genotype and Hypoglycemia Among Patients With Type 2 Diabetes Receiving Sulfonylurea Treatment: A Meta-analysis. | 2021 May |
7 |
| 4 |
34194474 | The Genetics of Adverse Drug Outcomes in Type 2 Diabetes: A Systematic Review. | 2021 |
1 |
| 5 |
34429480 | Impact of genetic and non-genetic factors on hepatic CYP2C9 expression and activity in Hungarian subjects. | 2021 Aug 24 |
1 |
| 6 |
34900803 | A pharmacogenetic pilot study of CYP2C9 common genetic variant and sulfonylureas therapeutic response in type 2 diabetes mellitus patients. | 2021 Dec |
5 |
| 7 |
31709648 | The presence of two reduced function variants in CYP2C9 influences the acute response to glipizide. | 2020 Dec |
1 |
| 8 |
32406758 | Inhibition of CYP2C9 by natural products: insight into the potential risk of herb-drug interactions. | 2020 May |
1 |
| 9 |
32504053 | Pharmacogenetics of hypoglycemia associated with sulfonylurea therapy in usual clinical care. | 2020 Dec |
1 |
| 10 |
32575674 | rs622342 in SLC22A1, CYP2C9*2 and CYP2C9*3 and Glycemic Response in Individuals with Type 2 Diabetes Mellitus Receiving Metformin/Sulfonylurea Combination Therapy: 6-Month Follow-Up Study. | 2020 Jun 20 |
2 |
| 11 |
32606720 | The Effect of CYP2C9 Genotype Variants in Type 2 Diabetes on the Pharmacological Effectiveness of Sulfonylureas, Diabetic Retinopathy, and Nephropathy. | 2020 |
2 |
| 12 |
33612460 | Pharmacogenetics of sulfonylurea: Presence of CYP2C9*2, CYP2C9*3 and a novel allele, CYP2C9*61, in Type 2 diabetes patients under sulfonylurea therapy. | 2020 Jul |
6 |
| 13 |
31086662 | Frequency of CYP2C9 (*2, *3 and IVS8-109A>T) allelic variants, and their clinical implications, among Mexican patients with diabetes mellitus type 2 undergoing treatment with glibenclamide and metformin. | 2019 May |
2 |
| 14 |
27958378 | Large-scale pharmacogenomic study of sulfonylureas and the QT, JT and QRS intervals: CHARGE Pharmacogenomics Working Group. | 2018 Jan |
1 |
| 15 |
28656666 | Interaction between variants in the CYP2C9 and POR genes and the risk of sulfonylurea-induced hypoglycaemia: A GoDARTS Study. | 2018 Jan |
4 |
| 16 |
26802434 | Personalized medicine in diabetes: the role of 'omics' and biomarkers. | 2016 Jun |
1 |
| 17 |
27180666 | [Pharmacogenetics of oral antidiabetic treatment]. | 2016 Mar |
1 |
| 18 |
27885968 | Possible approaches to CYP2C9-guided prescription of sulfonylureas in Russia. | 2016 Dec |
8 |
| 19 |
25077812 | Metabolism of agrochemicals and related environmental chemicals based on cytochrome P450s in mammals and plants. | 2015 Jun |
1 |
| 20 |
24464600 | CYP2C9*2 allele increases risk for hypoglycemia in POR*1/*1 type 2 diabetic patients treated with sulfonylureas. | 2014 Jan |
5 |
| 21 |
24590592 | Pharmacokinetics of tolbutamide and its metabolite 4-hydroxy tolbutamide in poloxamer 407-induced hyperlipidemic rats. | 2014 Jul |
1 |
| 22 |
23588782 | Applications of CYP450 testing in the clinical setting. | 2013 Jun |
2 |
| 23 |
24324494 | Pharmacogenetics of oral antidiabetic drugs. | 2013 |
3 |
| 24 |
23153186 | CYP2C metabolism of oral antidiabetic drugs--impact on pharmacokinetics, drug interactions and pharmacogenetic aspects. | 2012 Dec |
3 |
| 25 |
21142408 | Sulfonylureas and on-clopidogrel platelet reactivity in type 2 diabetes mellitus patients. | 2011 |
1 |
| 26 |
21213107 | Impact of clinical factors and CYP2C9 variants for the risk of severe sulfonylurea-induced hypoglycemia. | 2011 May |
3 |
| 27 |
21356265 | Reduced catalytic activity of human CYP2C9 natural alleles for gliclazide: molecular dynamics simulation and docking studies. | 2011 Jun |
1 |
| 28 |
21939641 | Impact of genetic polymorphisms of cytochrome P450 2 C (CYP2C) enzymes on the drug metabolism and design of antidiabetics. | 2011 Nov 15 |
1 |
| 29 |
19794412 | Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a Go-DARTS study. | 2010 Jan |
4 |
| 30 |
20222813 | Loss-of-function CYP2C9 variants: finding the correct clinical role for Type 2 diabetes pharmacogenetic testing. | 2010 Mar |
1 |
| 31 |
20698928 | Potential CYP2C9-mediated drug-drug interactions in hospitalized type 2 diabetes mellitus patients treated with the sulphonylureas glibenclamide, glimepiride or glipizide. | 2010 Oct |
2 |
| 32 |
21121772 | Effect of CYP2C9 polymorphisms on prescribed dose and time-to-stable dose of sulfonylureas in primary care patients with Type 2 diabetes mellitus. | 2010 Nov |
6 |
| 33 |
19891554 | Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas. | 2009 Nov |
9 |
| 34 |
17597710 | Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus. | 2008 Feb |
2 |
| 35 |
18503607 | Sitagliptin, an dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects. | 2008 Jul |
1 |
| 36 |
17963417 | Pharmacogenetics of glucose-lowering drug treatment: a systematic review. | 2007 |
1 |
| 37 |
15660356 | Herbicide resistance in transgenic plants with mammalian P450 monooxygenase genes. | 2005 Mar |
1 |
| 38 |
15963101 | Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents. | 2005 Jul |
2 |
| 39 |
16372821 | Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. | 2005 |
1 |
| 40 |
15349140 | CYP2C9 genotype as a predictor of drug disposition in humans. | 2004 Jul-Aug |
1 |
| 41 |
12405866 | Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. | 2002 |
2 |